Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Clinical trial NCT02169505 · TERMINATED
Trial details
- NCT number
- NCT02169505
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-22
- Primary completion
- 2017-08-14
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.